Salem Investment Counselors Inc. Sells 12,722 Shares of Boston Scientific Corporation $BSX

Salem Investment Counselors Inc. lessened its stake in Boston Scientific Corporation (NYSE:BSX) by 6.3% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 188,810 shares of the medical equipment provider’s stock after selling 12,722 shares during the period. Salem Investment Counselors Inc.’s holdings in Boston Scientific were worth $8,058,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Renaissance Group LLC acquired a new position in shares of Boston Scientific during the fourth quarter valued at $28,064,000. PensionDanmark Pensionsforsikringsaktieselskab grew its stake in shares of Boston Scientific by 9.9% during the second quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 320,038 shares of the medical equipment provider’s stock worth $13,659,000 after purchasing an additional 28,961 shares during the period. Meiji Yasuda America Inc bought a new stake in Boston Scientific in the fourth quarter valued at about $4,708,000. Harvest Portfolios Group Inc. increased its holdings in Boston Scientific by 6.1% in the fourth quarter. Harvest Portfolios Group Inc. now owns 597,341 shares of the medical equipment provider’s stock valued at $56,956,000 after purchasing an additional 34,598 shares during the last quarter. Finally, LBP AM SA lifted its stake in Boston Scientific by 8.4% in the fourth quarter. LBP AM SA now owns 434,393 shares of the medical equipment provider’s stock valued at $41,419,000 after buying an additional 33,534 shares during the period. Institutional investors own 89.07% of the company’s stock.

Insider Activity at Boston Scientific

In related news, Director Cheryl Pegus acquired 1,770 shares of the business’s stock in a transaction that occurred on Wednesday, May 20th. The shares were acquired at an average cost of $56.49 per share, with a total value of $99,987.30. Following the transaction, the director owned 1,770 shares of the company’s stock, valued at $99,987.30. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director David C. Habiger bought 2,100 shares of Boston Scientific stock in a transaction that occurred on Wednesday, August 5th. The stock was bought at an average cost of $47.59 per share, with a total value of $99,939.00. Following the completion of the purchase, the director owned 17,160 shares in the company, valued at approximately $816,644.40. This trade represents a 13.94% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders have acquired 204,322 shares of company stock valued at $9,939,221. Insiders own 0.34% of the company’s stock.

Analyst Upgrades and Downgrades

BSX has been the subject of several analyst reports. Raymond James Financial restated an “outperform” rating and set a $57.00 target price on shares of Boston Scientific in a research report on Thursday, July 30th. UBS Group cut their price target on shares of Boston Scientific from $74.00 to $67.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. Citigroup reduced their price objective on shares of Boston Scientific from $70.00 to $61.00 and set a “buy” rating on the stock in a research note on Thursday, July 30th. Barclays decreased their price objective on shares of Boston Scientific from $96.00 to $89.00 and set an “overweight” rating for the company in a report on Thursday, May 28th. Finally, Robert W. Baird set a $56.00 target price on shares of Boston Scientific in a research note on Thursday, July 30th. Twenty-four research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $71.62.

Boston Scientific Price Performance

Shares of BSX opened at $51.40 on Thursday. The stock has a 50 day simple moving average of $45.94 and a 200 day simple moving average of $59.69. Boston Scientific Corporation has a 52-week low of $42.20 and a 52-week high of $109.50. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24. The firm has a market capitalization of $74.49 billion, a PE ratio of 20.81, a P/E/G ratio of 1.12 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, topping the consensus estimate of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The firm had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. During the same period last year, the company posted $0.75 EPS. The business’s quarterly revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Sell-side analysts predict that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.

Boston Scientific announced that its Board of Directors has initiated a share buyback plan on Monday, May 18th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s board believes its shares are undervalued.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.